Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 17/20 | 0.67 |
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933579 | 0.86 | AOC3 (0.62) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3933584 | 0.86 | AOC3 (0.62) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3932588 | 0.86 | AOC3 (0.71) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3943351 | 0.85 | AOC3 (0.69) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3939152 | 0.85 | AOC3 (0.73) | AOC3MAOBSMN1; SMN2KMT2A | |
| SCHEMBL3939971 | 0.85 | AOC3 (0.73) | AOC3MAOBSMN1; SMN2KMT2A | |
| SCHEMBL5550194 | 0.84 | AOC3 (0.68) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3943479 | 0.84 | AOC3 (0.68) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL5545444 | 0.83 | AOC3 (0.59) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL5545443 | 0.83 | AOC3 (0.59) | AOC3MAOBSMN1; SMN2KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1786792-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006011631-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 386/4885MAOB 3666/4885SMN1; SMN2 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.